China NMPA Accepts Sacituzumab Tirumotecan Combination Application for Review
China's NMPA accepted for review an application for sacituzumab tirumotecan with pembrolizumab as a first-line treatment for PD-L1-negative non-squamous NSCLC.
Related stories
Canada Calls on Cleveland-Cliffs to Recall Laid-Off Stelco Workers
Canada's government says Cleveland-Cliffs must immediately recall laid-off Stelco workers and provide a credible, concrete jobs plan before a meeting with the company's CEO.
L impact | REGULATION | Oct 29, 2026, 04:55 PM UTC
New Jersey Governor Threatens to Block Russian Diesel Cargoes
L impact | REGULATION | Oct 29, 2026, 04:43 PM UTC
US Judge Blocks Trump Limits on Medicaid Work-Requirement Exceptions
A US judge blocked Trump administration limits on exceptions to Medicaid work requirements, according to Reuters.
M impact | REGULATION | Oct 29, 2026, 04:41 PM UTC
Medline to Remove or Correct Branded Beds and Accessories Over Safety Risks
The FDA says Medline is discontinuing and removing or correcting branded beds and accessories over safety risks.
M impact | REGULATION | Oct 29, 2026, 04:36 PM UTC
Ohio AG Seeks $220 Million From GM Over Alleged Data Sales
Ohio Attorney General says General Motors was asked to pay $220 million over the alleged sale of consumers’ driving behavior and location data.
M impact | REGULATION | Oct 29, 2026, 04:31 PM UTC
Venezuela to Offer State Assets to Private Sector, Rodriguez Says
M impact | REGULATION | Oct 29, 2026, 04:28 PM UTC